Analysis of Genomic DNA Alterations in Familial Schizophrenia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00166738
First received: September 11, 2005
Last updated: August 23, 2007
Last verified: September 2005
  Purpose

Persons with schizophrenia experience imaginary voices, visions and disorganized thoughts, and are handicapped when it comes to social life, which is detrimental to the affected individuals and the community. Although the pathogenesis of this mental disease has not been clearly elucidated, much evidence suggests that inheritance is of major etiological importance and multiple genetic components are implicated. Previous linkage studies of familial schizophrenia have led to the successful identification of numerous susceptibility loci covering many of the human chromosomes, including chromosome 1q, 5q, 6p22, 6p24, 8q21, 13q32, 15q13-14 and 22q11, etc. Necessities for further identification of candidate genes involved in familial schizophrenia by taking a genome-wide approach are listed as follows:

  1. given that multiple genes are responsible for this disease, it is of critical interest to view the complete molecular profiling of schizophrenia's genome;
  2. identification of promising schizophrenia candidate genes by genome-wide scanning will facilitate the development of molecular markers and provide a more objective and effective assessment method in psychotic diagnosis and prognosis;
  3. prevention of the onset of this disorder will be improved by early classification of individuals bearing strong genetic loading for schizophrenia as a high risk population;
  4. making a breakthrough into the investigation of schizophrenia pathogenesis by the characterization of susceptible genes found by genome-wide exploring.

Array-based comparative genomic hybridization (CGH) allows high-throughput genome-wide survey for DNA copy number aberrations, providing a powerful tool for investigating genetic disorders and for developing diagnostic and therapeutic targets. Arrays used in this study consist of approximately 43,000 60-mer oligonucleotide probes that span coding and noncoding regions of the whole human genome with an average spatial resolution of around 35 kb. Furthermore, the sensitivity of these arrays is capable of detecting and mapping regions of single-copy losses, homozygous deletions, and amplicons of various sizes even when using full-complexity genomic samples. In this study, the investigators will conduct an array-based comparative genomic hybridization (CGH) with genomic DNA of many affected members from "schizophrenia families" (the investigators classified families according to the presence or absence of two or more affected members) to identify a set of candidate genes associated with this disease. It is hoped that the results obtained from this study will improve the accuracy and efficiency of psychotic treatment.


Condition
Schizophrenia

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Analysis of Genomic DNA Alterations in Familial Schizophrenia

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 20
Study Start Date: September 2005
Estimated Study Completion Date: December 2005
  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Familial schizophrenia
  • Over 9 years of education
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00166738

Contacts
Contact: Hai-Gwo Hwu, Professor 886-2-2312-3456 ext 6785 haigohwu@ha.mc.ntu.edu.tw

Locations
Taiwan
Hai-Gwo Hwu Recruiting
Taipei, Taiwan
Contact: Hai-Gwo Hwu, Professor    886-2-2312-3456 ext 6785      
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Hai-Gwo Hwu, Professor National Taiwan University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00166738     History of Changes
Other Study ID Numbers: 9461700834
Study First Received: September 11, 2005
Last Updated: August 23, 2007
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Schizophrenia
multiple genes
array-comparative genomic hybridization (CGH)
genomic DNA
Chinese Han People

Additional relevant MeSH terms:
Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on October 29, 2014